Australian biotech market watch 17/11/09
Tuesday, 17 November, 2009
The All Ordinaries has retracted after seeing a surge in early trading. As of 2.45pm this afternoon it's down 18 points to 4,755 from a of 4,809 at 10am.
Xenotransplantation specialists, Living Cell Technologies (ASX:LCT), are up by 9.5% to 29c after its announcement of a share purchase plan yesterday. This means the price of 25c per share being offered by LCT is equivalent to a 15% discount from the current price.
Prima Biomed (ASX:PRR) issued a trading halt this morning pending an announcement of an oral vaccine for cervical cancer. It last traded at 16.5c, up 3.1%.
Mesoblast (ASX:MSB) also saw impressive gains this morning, up 8c to $1.36. Cancer drug company, ChemGenex, put on 3.7% to 98.5c.
Also experiencing rises were Sirtex (ASX:SRX), up 16c to $6.66, Ramsay Health Care (ASX:RHC), up 12c to $10.91 and Cellestis (ASX:CST), up 4c to $3.84.
Falls were seen by Blackmores (ASX:BKL), down 1.4% to $20.71, and Ansell (ASX:ANN), down a similar amount to $10.26.
The majors remained fairly steady.
Pig-to-human liver xenotransplant conducted in a living recipient
The case involved a 71-year-old man with hepatitis B-related cirrhosis and hepatocellular...
Inhaled form of blood thinner treats serious COVID infections
Heparin has traditionally been injected and used to treat blood clots, but the new study tested...
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
